Every New York stock exchange trading day I’m posting a daily dividend stock or fund review. I’ll share the three chief qualities of just one equity or fund that could be selected for a dividend stock portfolio I’ve named the Safari to Sweet Success.

This week my Safari portfolio seeks a company in the healthcare sector. 

That sector includes ten industries all related to testing, diagnosing and treating what ails us. The healthcare industries are: biotechnology; diagnostics & research; drug manufacturers – major; drug manufacturers – specialty & generic; healthcare plans; long-term care facilities; medical care; medical devices, medical distribution; medical supplies.

Today I’m reviewing a biotechnology company, Grifols, S.A. Its trading ticker symbol is GRFS. 

Grifols, S.A. collects the liquid portion of human blood called plasma and then manufactures and sells plasma-derived products globally. It also operates diagnostics, hospital supplies, and raw materials businesses.

The company distributes biological medicines on plasma-derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. 

Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

I use three primary keys to gauge dividend equities or funds like Grifols, S.A. (GRFS): 

(1) Price

(2) Dividends

(3) Returns

GRFS Price

Grifols’s price at yesterday’s market close was $22.47 per share.A year ago its price was $17.49. Yes, it gained$5.98 per share in the past year.  

If GRFS does as well this coming year its value will increase from $22.47 to $27.45, or about 26.6%. 

GRFS Dividends

Grifols’s most recent annual dividend was $0.385 paid semi-annually in June and December.